株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の免疫チェックポイント阻害薬市場:タイプ(CTLA-4阻害薬、PD-1阻害薬, PD-L1阻害薬)、応用領域(肺がん、膀胱がん、悪性黒色腫、ホジキンリンパ腫)、地域別 - 市場機会の分析と産業予測 2018年〜2025年

Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor) and Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025

発行 Allied Market Research 商品コード 724043
出版日 ページ情報 英文 149 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.34円で換算しております。
Back to Top
世界の免疫チェックポイント阻害薬市場:タイプ(CTLA-4阻害薬、PD-1阻害薬, PD-L1阻害薬)、応用領域(肺がん、膀胱がん、悪性黒色腫、ホジキンリンパ腫)、地域別 - 市場機会の分析と産業予測 2018年〜2025年 Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor) and Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025
出版日: 2018年09月01日 ページ情報: 英文 149 Pages
概要

世界の免疫チェックポイント阻害薬市場は、2017年に105億4000万米ドルと評価され、2018年から2025年にかけては25.6%のCAGRで推移し、2025年までに654億2700万米ドル規模の市場に成長することが予測されています。

当レポートでは、世界の免疫チェックポイント阻害薬市場を調査し、市場の概要、タイプ・応用領域・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • レポートの説明
  • ステークホルダーの主な利点
  • 主な市場セグメント
    • 主要企業
  • 調査方法
    • 2次調査
    • 1次調査
    • アナリストツールとモデル

第2章 エグゼクティブサマリー

  • 調査結果

第3章 市場概要

  • 市場の定義と範囲
  • 主な所見
  • 市場のダイナミクス
    • 成長要因
    • 阻害要因
    • 市場機会
    • 影響分析
  • 臨床試験
  • パイプライン分析

第4章 免疫チェックポイント阻害薬市場:タイプ別

  • 概要
    • 市場規模と予測
  • CTLA-4阻害薬
    • 主な市場動向、成長要因、市場機会
    • 市場規模と予測
  • PD-1阻害薬
  • PD-L1阻害薬

第5章 免疫チェックポイント阻害薬市場:用途別

  • 概要
    • 市場規模と予測
  • 肺がん
  • 膀胱がん
  • 悪性黒色腫
  • ホジキンリンパ腫
  • その他

第6章 免疫チェックポイント阻害薬市場:地域別

  • 概要
    • 市場規模と予測
  • 北米
    • 主な市場動向、成長要因、市場機会
    • 市場規模と予測:国別
    • 市場規模と予測:タイプ別
    • 市場規模と予測:用途別
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ

第7章 企業プロファイル

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Fortress Biotech, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Immutep Limited
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
図表

List of Tables

  • TABLE 01. CLINICAL TRIALS IN IMMUNE CHECKPOINT INHIBITORS MARKET, 2015-2018
  • TABLE 02. PRODUCT PIPELINE ANALYSIS (PHASE II & III)
  • TABLE 03. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 04. CTLA-4 INHIBITOR MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 05. PD-1 INHIBITOR MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 06. PD-L1 INHIBITOR MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 07. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
  • TABLE 08. LUNG CANCER IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 09. BLADDER CANCER IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 10. MELANOMA IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 11. HODGKIN LYMPHOMA IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 12. OTHERS IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 13. IMMUNE CHECKPOINT INHIBITORS MARKET REVENUE, BY REGION, 2017-2025 ($MILLION)
  • TABLE 14. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 15. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 16. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
  • TABLE 17. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 18. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 19. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
  • TABLE 20. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 21. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 22. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
  • TABLE 23. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 24. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 25. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
  • TABLE 26. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 27. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 28. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 29. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 30. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 31. LILLY: COMPANY SNAPSHOT
  • TABLE 32. LILLY: OPERATING SEGMENTS
  • TABLE 33. LILLY: PRODUCT PORTFOLIO
  • TABLE 34. FORTRESS: COMPANY SNAPSHOT
  • TABLE 35. FORTRESS: OPERATING SEGMENTS
  • TABLE 36. FORTRESS: PRODUCT PORTFOLIO
  • TABLE 37. ROCHE: COMPANY SNAPSHOT
  • TABLE 38. ROCHE: OPERATING SEGMENTS
  • TABLE 39. ROCHE: PRODUCT PORTFOLIO
  • TABLE 40. IMMUTEP: COMPANY SNAPSHOT
  • TABLE 41. IMMUTEP: PRODUCT PORTFOLIO
  • TABLE 42. MERCK: COMPANY SNAPSHOT
  • TABLE 43. MERCK: OPERATING SEGMENTS
  • TABLE 44. MERCK: PRODUCT PORTFOLIO
  • TABLE 45. MERCK: COMPANY SNAPSHOT
  • TABLE 46. MERCK: OPERATING SEGMENTS
  • TABLE 47. MERCK: PRODUCT PORTFOLIO
  • TABLE 48. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 49. NOVARTIS: OPERATING SEGMENTS
  • TABLE 50. NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 51. PFIZER: COMPANY SNAPSHOT
  • TABLE 52. PFIZER: OPERATING SEGMENTS
  • TABLE 53. PFIZER: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 01. IMMUNE CHECKPOINT INHIBITORS MARKET SEGMENTATION
  • FIGURE 02. TOP INVESTMENT POCKETS
  • FIGURE 03. TOP PLAYER POSITIONING, 2017
  • FIGURE 04. WORLD POPULATION AGED 65 AND OVER (%)
  • FIGURE 05. IMPACT ANALYSES
  • FIGURE 06. U.S. IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
  • FIGURE 07. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
  • FIGURE 08. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
  • FIGURE 09. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
  • FIGURE 10. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
  • FIGURE 11. UK IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
  • FIGURE 12. REST OF EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
  • FIGURE 13. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
  • FIGURE 14. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
  • FIGURE 15. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
  • FIGURE 16. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
  • FIGURE 17. REST OF ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
  • FIGURE 18. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
  • FIGURE 19. REST OF LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
  • FIGURE 20. ASTRAZENECA: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 21. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 22. REVENUE, 2015-2017 ($MILLION)
  • FIGURE 23. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 24. REVENUE, 2015-2017 ($MILLION)
  • FIGURE 25. LILLY: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 26. LILLY: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 27. FORTRESS: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 28. FORTRESS: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 29. ROCHE: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 30. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 31. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 32. IMMUTEP: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 33. MERCK: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 34. MERCK: NET SALES BY SEGMENT, 2017 (%)
  • FIGURE 35. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)
  • FIGURE 36. MERCK: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 37. MERCK: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 38. MERCK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 39. NET SALES, 2015-2017 ($MILLION)
  • FIGURE 40. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 41. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 42. PFIZER: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 43. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 44. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
目次
Product Code: LI_183723

The global immune checkpoint inhibitors market was valued at $10,540 million in 2017, and is projected to reach $65,427 million by 2025, registering a CAGR of 25.6% from 2018 to 2025.

Checkpoint inhibitor is a type of drug used in immunotherapy, which helps block the proteins present on tumor cells, as these affect the functioning of the immune system. Immune checkpoint inhibitor drugs block different checkpoint proteins, including cytotoxic T lymphocyte associated protein 4 (CTLA-4), programmed cell death protein (PD-1), and programmed death ligand 1 (PD-L1). Immune checkpoint inhibitors have witnessed increasing demand, owing to increase in incidence of different forms of cancer, surge in awareness of checkpoint inhibitors for the treatment of cancer, higher number of pipeline drugs, and upsurge in adoption of immune checkpoint inhibitor drugs. In addition, growth in the geriatric population and technological advancements in screening & diagnosis of cancer drive the market growth. However, high cost associated with immune checkpoint inhibitors is projected to impede the market growth.

The global immune checkpoint inhibitor market is segmented based on type, application, and region. On the basis of type, the market is classified as CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. The applications covered in the study include lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS:

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS:

By Type

  • CTLA-4 Inhibitor
  • PD-1 Inhibitor
  • PD-L1 Inhibitor

By Application

  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Hodgkin Lymphoma
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT:

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company (ARMO Biosciences)
  • Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
  • F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
  • Immutep Limited
  • Merck & Co., Inc.
  • Merck KGaA (EMD Serono, Inc.)
  • Novartis AG
  • Pfizer Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN:

(These players are not profiled in the report. The same will be included on request.)

  • Incyte Corporation
  • NewLink Genetics

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits for stakeholders
  • 1.3. Key market segments
    • 1.3.1. List of key players profiled in the report
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. Key findings of the study
    • 2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
    • 3.2.2. Top player positioning
  • 3.3. MARKET DYNAMICS
    • 3.3.1. Drivers
      • 3.3.1.1. Increase in incidence of cancer across the globe
      • 3.3.1.2. Surge in global geriatric population
      • 3.3.1.3. Supportive reimbursement policies for immune checkpoint inhibitors
      • 3.3.1.4. Surge in healthcare expenditure worldwide
    • 3.3.2. Restraint
      • 3.3.2.1. Higher cost of immune checkpoint inhibitors
    • 3.3.3. Opportunities
      • 3.3.3.1. Increase in number of pipeline drugs
      • 3.3.3.2. Growth opportunities in the emerging markets
    • 3.3.4. Impact analyses
  • 3.4. Clinical trials
  • 3.5. Pipeline analyses

CHAPTER 4: IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. CTLA-4 inhibitor
    • 4.2.1. Key market trends, growth factors, and opportunities
    • 4.2.2. Market size and forecast
  • 4.3. PD-1 inhibitor
    • 4.3.1. Key market trends, growth factors, and opportunities
    • 4.3.2. Market size and forecast
  • 4.4. PD-L1 inhibitor
    • 4.4.1. Key market trends, growth factors, and opportunities
    • 4.4.2. Market size and forecast

CHAPTER 5: IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Lung cancer
    • 5.2.1. Market size and forecast
  • 5.3. Bladder cancer
    • 5.3.1. Market size and forecast
  • 5.4. Melanoma
    • 5.4.1. Market size and forecast
  • 5.5. Hodgkin lymphoma
    • 5.5.1. Market size and forecast
  • 5.6. Others
    • 5.6.1. Market size and forecast

CHAPTER 6: IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors, and opportunities
    • 6.2.2. North America market size and forecast, by country
      • 6.2.2.1. U.S.
      • 6.2.2.2. Canada
      • 6.2.2.3. Mexico
    • 6.2.3. North America market size and forecast, by type
    • 6.2.4. North America market size and forecast, by application
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors, and opportunities
    • 6.3.2. Europe market size and forecast, by country
      • 6.3.2.1. Germany
      • 6.3.2.2. France
      • 6.3.2.3. UK
      • 6.3.2.4. Rest of Europe
    • 6.3.3. Europe market size and forecast, by type
    • 6.3.4. Europe market size and forecast, by application
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors, and opportunities
    • 6.4.2. Asia-Pacific market size and forecast, by country
      • 6.4.2.1. Japan
      • 6.4.2.2. China
      • 6.4.2.3. Australia
      • 6.4.2.4. India
      • 6.4.2.5. Rest of Asia-Pacific
    • 6.4.3. Asia-Pacific market size and forecast, by type
    • 6.4.4. Asia-Pacific market size and forecast, by application
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors, and opportunities
    • 6.5.2. LAMEA market size and forecast, by country
      • 6.5.2.1. Brazil
      • 6.5.2.2. Rest of LAMEA
    • 6.5.3. LAMEA market size and forecast, by type
    • 6.5.4. LAMEA market size and forecast, by application

CHAPTER 7: COMPANY PROFILES

  • 7.1. AstraZeneca Plc.
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segments
    • 7.1.4. Product Portfolio
    • 7.1.5. Business performance
    • 7.1.6. Key strategic moves and developments
  • 7.2. Bristol-Myers Squibb Company
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Operating business segments
    • 7.2.4. Product portfolio
    • 7.2.5. Business performance
    • 7.2.6. Key strategic moves and developments
  • 7.3. Eli Lilly and Company (ARMO BioSciences)
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Operating business segments
    • 7.3.4. Product Portfolio
    • 7.3.5. Business performance
  • 7.4. Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Operating business segments
    • 7.4.4. Product portfolio
    • 7.4.5. Business performance
  • 7.5. F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segments
    • 7.5.4. Product portfolio
    • 7.5.5. Business performance
    • 7.5.6. Key strategic moves and developments
  • 7.6. Immutep Limited
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
    • 7.6.3. Operating business segments
    • 7.6.4. Product Portfolio
    • 7.6.5. Business performance
  • 7.7. Merck & Co., Inc.
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Operating business segments
    • 7.7.4. Product Portfolio
    • 7.7.5. Business performance
    • 7.7.6. Key strategic moves and developments
  • 7.8. Merck KGaA (EMD Serono, Inc.)
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Operating business segments
    • 7.8.4. Product Portfolio
    • 7.8.5. Business performance
    • 7.8.6. Key strategic moves and developments
  • 7.9. Novartis AG
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Operating business segments
    • 7.9.4. Product Portfolio
    • 7.9.5. Business performance
  • 7.10. Pfizer Inc.
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Operating business segments
    • 7.10.4. Product Portfolio
    • 7.10.5. Business performance
    • 7.10.6 Key strategic moves and development
Back to Top